The release of added context on the benefit-risk profile of CAR-T therapies underscores how safety is moving from the periphery into the category’s forefront.
Judge rebuffs PhRMA lawsuit over Medicare power to negotiate drug prices
It’s been a tumultuous 18 months since the passage of Medicare drug price negotiations punctured the lobbying group’s ‘aura of invincibility.’ Is it time for a policy revamp at PhRMA?
Loading...
MM+M Transform: The Patient, Provider and Payer Engagement Matrix